{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260625926870/en/FDA-Approves-KEYTRUDA%C2%AE-pembrolizumab-and-KEYTRUDA-QLEX%E2%84%A2-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-with-Trodelvy%C2%AE-sacituzumab-govitecan-hziy-as-First-Line-Treatment-of-PD-L1-CPS-%E2%89%A510-Advanced-Triple-Negative-Breast-Cancer-TNBC", "message": "News view counter 816164 successfully enlarged"}